New York Presbyterian Hospital (Columbia Campus) Child Neurology

Topics

• Epilepsy research and treatment 213
• Mitochondrial Function and Pathology 68
• Neurogenetic and Muscular Disorders Research 36
• Genetics and Neurodevelopmental Disorders 31
• Cerebral Palsy and Movement Disorders 27
• Genomics and Rare Diseases 27
• Glioma Diagnosis and Treatment 27
• Neonatal and fetal brain pathology 26
• Attention Deficit Hyperactivity Disorder 25
• Neuroscience and Neuropharmacology Research 24
• Metabolism and Genetic Disorders 18
• Research in Cotton Cultivation 18

Most cited

1. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.

   The Lancet. Neurology · 2021 · 399 citations · Claudia Chiriboga

2. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.

   Nature medicine · 2022 · 263 citations · Claudia Chiriboga

3. Association of Birth During the COVID-19 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to Maternal SARS-CoV-2 Infection.

   JAMA pediatrics · 2022 · 217 citations · Jennifer Bain, Arthur Mandel, Danielle McBrian, Wendy Silver

4. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.

   The Lancet. Neurology · 2022 · 182 citations · Anna Jeong

5. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.